CT Clinical Trials in Boston, Massachusetts
416 recruitingBoston, Massachusetts
Showing 1–20 of 416 trials
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma+1 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting
Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled28 locationsNCT07213791
Recruiting
Phase 1
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled1 locationNCT07137416
Recruiting
Phase 2
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Breast CarcinomaBreast Atypical Ductal HyperplasiaBreast Atypical Lobular Hyperplasia
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting
Phase 1
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI)57 enrolled6 locationsNCT05422794
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Breast Cancer MetastaticPancreatic CancerHER2-negative Breast Cancer+9 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting
Phase 4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Cognitive FunctionMotor FunctionContrast Media
Guerbet2,076 enrolled51 locationsNCT04373564
Recruiting
Not Applicable
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
Breast CancerChemotherapy EffectExercise Therapy+1 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT04724499
Recruiting
Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
Not Applicable
Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
Breast Reconstruction
Amy Colwell212 enrolled1 locationNCT07209436
Recruiting
Phase 1
IKS014 in Advanced Solid Tumors That Express HER2
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.165 enrolled12 locationsNCT05872295
Recruiting
Not Applicable
The COMPASSION Study
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Dana-Farber Cancer Institute200 enrolled1 locationNCT06507930
Recruiting
Phase 1Phase 2
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Triple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Lung CancerAdvanced Solid TumorMetastatic Solid Tumor+2 more
Circle Pharma220 enrolled10 locationsNCT06577987
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Phase 2
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Stage III Breast CancerTriple-Negative Breast CarcinomaRecurrent Breast Carcinoma+6 more
Laura Huppert, MD, BA150 enrolled12 locationsNCT03971409